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Summary
Background.— Concern about procedure-related bleeding is a major reason for premature dis-
continuation of dual oral antiplatelet therapy (APT); treatment cessation is detrimental in
patients with coronary artery disease (CAD), especially after drug-eluting stent (DES) place-
ment. The nationwide REGINA survey was designed to evaluate how the interruption of dualPractice variation APT is managed in the ‘real world’.
Methods.— Physicians (2700/4581) were randomly selected to participate in a computer-
assisted telephone interview. Knowledge about DES and APT was appraised by multiple-choice
questions. Strategies for temporary interruption of dual APT before an invasive or surgical pro-
cedure were evaluated using 21 scenarios, including high-risk (30 days after DES) and low-risk
(18 months after DES) periods.
 REGINA: registre sur la gestion de l’interruption des antiagrégants plaquettaires oraux chez le coronarien.
 The results of this study were presented in part at the Congress of the European Society of Cardiology, September 2007.
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Results.— Out of 2700 practitioners, 2515 completed the interview. Rates of correct answers
to basic knowledge questions ranged from 0% (dentists) to 52% (cardiologists). Unjustiﬁed
total interruption of dual APT was much more frequent than expected (22.0% vs. 11.8%). A
strategy of total interruption was less frequently chosen in the period of high ischemic risk
compared to the low-risk period (13.7% vs. 31.1%, p < 0.0001). Dual APT interruption in patients
who require additional invasive cardiac or surgical procedures depended on type of physician
consulted (more frequent in specialists than general practitioners or dentists), and on the physi-
cian’s age and practice type (rural/private vs. urban/hospital). Correct answers were more
frequently given in situations bearing a major risk, either ischemic or bleeding risk, than in
those with no risk (49.2% vs. 30.2%, p < 0.0001). Low-molecular-weight heparin was the substi-
tution therapy in over two-thirds of scenarios and was associated with longer periods of APT
interruption.
Interpretation.— Adequate management of APT in patients with intracoronary stents who
undergo potentially haemorrhagic invasive procedures depends mainly on the type of physician
involved and their practice rather than on a carefully weighted assessment of ischemic/bleeding
risk. Our ﬁndings suggest a lack of scientiﬁc evidence, insufﬁcient knowledge of guidelines, and
poor communication between physicians managing these patients.
© 2009 Elsevier Masson SAS. All rights reserved.
MOTS CLÉS
Antiagrégant oral ;
Maladie coronaire ;
Pratique médicale
Résumé
Rationel.— Le saignement lié aux procédures invasives est l’une des principales causes
d’interruption prématurée de la bithérapie antiagrégante plaquettaire (BAP) orale
(aspirine + clopidogrel). L’arrêt de cette dernière est délétère en particulier chez les patients
coronariens ayant bénéﬁcié d’une angioplastie coronaire avec stent actif. Le registre national
Regina a été mis en place pour évaluer les modalités d’interruption de cette bithérapie dans la
vraie vie.
Méthode.— Les médecins (2700/4581) ont été tirés au sort pour participer à une interview
téléphonique. Les connaissances de base sur les stents actifs et la BAP orale ont été évaluées
par des questions à choix multiples. Les stratégies d’interruption temporaire de la BAP avant
un geste invasif ont été évaluées par 21 scénarios comprenant à chaque fois des situations à
haut risque (dans les 30 premiers jours suivant la mise en place d’un stent actif) ou à faible
risque de complications ischémiques adaptés à chaque type de praticien. Le critère primaire
de jugement était le taux d’interruption complète de la BAP.
Résultats.— Sur 2700 praticiens, 2515 ont complété l’interview. Le taux de réponses correctes
à l’évaluation des connaissances de base allait de 0% (dentiste) à 52 % (cardiologues). L’arrêt
complet et injustiﬁé de la BAP était bien plus fréquent qu’attendu (22,0 % versus 11,8 %). Une
stratégie d’interruption complète était moins fréquemment choisie dans les situations de haut
risque par rapport aux situations à faible risque (13,7 % versus 31,1 %, p < 0,0001). La décision
d’interruption avant un geste invasif ou chirurgical dépendait à la fois du type de spécialité
(plus fréquent dans les spécialités médicotechniques qu’en médecine générale ou en cabinet
dentaire), mais aussi de l’âge du praticien et de son type d’exercice (rurale versus urbain,
privé versus hospitalier). Les réponses correctes étaient plus fréquentes dans les situations à
haut risque (ischémique ou hémorragique) que dans les situations ne comportant aucun risque
particulier (49,2 % versus 30,2 %, p < 0,0001). Les héparines de bas poids moléculaires représen-
taient le traitement de substitution dans plus de deux tiers des scénarios et leur utilisation
était associée à une durée plus longue d’interruption de la BAP.
Interprétation.— L’interruption de la BAP chez les patients « stentés » et devant bénéﬁcier d’un
geste invasive à risque hémorragique potentiel dépend davantage du type de praticien et de
leur pratique que d’une évaluation rigoureuse du rapport risque/bénéﬁce liée à la situation.
Nos résultats indiquent le manque de données scientiﬁques mais aussi une connaissance insuff-
isante des recommandations et l’absence de communication entre les praticiens soumis à ces
. Tou
I
D
e
isituations.
© 2009 Elsevier Masson SASntroduction
iscontinuation of antiplatelet therapy in patients with
stablished coronary artery disease (CAD) has become an
ncreasingly important concern. Evidence has arisen that
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bs droits réservés.topping aspirin in patients with stable CAD treated with
spirin alone leads to an increased risk of acute coronary
yndrome (ACS) and death [1,2]. This potential hazard is
mpliﬁed by the large numbers of patients treated with
are-metal stents (BMS) and drug-eluting stents (DES) [3]
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who are receiving long-term dual oral antiplatelet therapy
(APT). The risk of APT interruption in these patients is even
higher, especially when DES have been used [4—9].
Recent recommendations from the European Society of
Cardiology and the American Heart Association [10—12]
have warned against premature and unjustiﬁed interrup-
tion of APT. The bleeding hazard often does not justify the
interruption of APT. Recommendations from different scien-
tiﬁc societies, including gastroenterologists, anaesthetists,
lung specialists and dentists, have provided some important
practical guidelines [13—16]. However, exaggerated con-
cern about increased procedure-related bleeding remains
the major factor for premature discontinuation of APT. The
ischaemic hazard related to discontinuation of APT depends
on many factors, of which the context of recent stent
implantation in ACS is certainly the most critical. This is
why a recent advisory committee/consensus group stressed
the importance of 12 months of dual APT after DES implan-
tation and of educating patients and healthcare providers
about the hazards of premature discontinuation [10,12].
Educating physicians and healthcare providers has
become a critical aspect of good clinical practice. Tempo-
rary discontinuation (< 15 days) of APT because of planned
invasive procedure is handled mainly by noncardiologists;
these practitioners are very sensitive to recommendations
from their national societies. In addition, a real-life situa-
tion clearly lacks prospective and scientiﬁc evaluation, and
physicians are often unsure how to approach this dilemma.
The registre sur la gestion de l’interruption des antia-
grégants plaquettaires oraux chez le coronarien (REGINA)
survey was designed to evaluate how interruption of dual
APT is handled in the real world by different categories of
practitioner. Our major aim was to evaluate the rate of com-
plete interruption of dual APT according to the period at risk
of stent thrombosis for each category of physician and as to
whether complete interruption was justiﬁed or not.
Methods
Evaluation of basic knowledge
Evaluation of basic knowledge was performed by determin-
ing the rate of correct answers to three multiple-choice
questions (Appendix A). For each question, there were ﬁve
possible responses. The ﬁrst question referred to the deﬁni-
tion of a DES. The other two related to theminimum duration
of dual APT following BMS and DES placement.
A scientiﬁc advisory board was created to validate
the questionnaires and to determine the expected correct
answers, based on the recommendations in all currently
available guidelines [13—15]. Correct answers are high-
lighted in bold and italics in the Appendix B.
Evaluation of interruption strategies
Interruption strategies following DES were evaluated for
periods of high risk (30 days after DES implantation) and
low risk (18 months after DES implantation). In the high-risk
situation, discontinuation was considered (by the scien-
tiﬁc committee) as detrimental because of the high risk of
ischaemic events whereas the bleeding risk was acceptable.
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n the low-risk situation, discontinuation was considered (by
he scientiﬁc committee) to be mandatory because of the
ow risk of ischaemic events and the high bleeding risk.
Both situations were evaluated by one or two simple
ultiple-choice questions (Appendix B). All questions were
onstructed using a unique pattern of six possibilities, deliv-
red in the same order to facilitate the interview. The
rst choice was postponing the procedure. The second was
ontinuation of both aspirin and clopidogrel during the
rocedure. The third and the fourth choices were partial
iscontinuation of dual APT, either aspirin or clopidogrel.
he ﬁfth was temporary complete interruption of dual APT.
he last choice was ‘Don’t know’, but this response was
iscouraged.
Each situation was tailored according to the category of
hysician. Concordance was assessed systematically by an
dditional question in which the physician had to consider
hemselves as the patient. Management of APT interrup-
ion, either complete or partial, was carefully evaluated
hen it was the chosen strategy. In particular, the time
elay of interruption before the procedure and substitu-
ion therapy with either low-molecular-weight heparin or a
on-steroidal anti-inﬂammatory drug (NSAID) were carefully
ssessed (Appendix C).
tudy population and computed-assisted
elephone interview technique
ational scientiﬁc societies for each category of physician
ere contacted and asked to participate in the study. Their
asks were to nominate a member of the scientiﬁc board and
o provide a list of physicians recognised as members who
ould potentially participate in the study. Exclusion criteria
ere retirement and absence of clinical practice.
A specialised consulting agency (IPSOS Insight Santé,
aris, France) was responsible for undertaking the inter-
iews. The computed-assisted telephone interview method
as chosen to avoid selection bias and to give each potential
hysician the same probability of being interviewed. This
pproach allowed direct quoting of the answers and auto-
atic and random delivery of the questionnaire. In addition,
ach choice of question was randomly delivered. The rate of
efusal and of abandon was monitored, as well as real-time
ollow-up of the overall study sample.
To expedite the telephone interviews and to prevent a
igh rate of refusal, all members of staff who performed the
nterviews participated in a training session on APT and on
cientiﬁc interview techniques. A letter outlining the objec-
ives of the REGINA study and the methodological approach
as sent on behalf of the advisory board to all potential
articipants ﬁve days before random selection.
tatistical analyses
he frequency of different answers was compared using the
hi2 test. Multivariable stepwise logistic regression analysis
as carried out to identify independent correlates of cor-
ect answers, both in the whole sample of practitioners and
n each category. Concordance between the answers from
ach practitioner to high-risk situations in which ‘the doc-
or was the patient’ and ‘the doctor was not the patient’
as estimated by the Kappa coefﬁcient. The two-sided sig-
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iﬁcance level was ﬁxed at 5%. All analyses were performed
sing SAS 9.1.3 (SAS Institute).
ole of the funding source
he study sponsors had no involvement in the study design;
n the collection, analysis, and interpretation of data; in the
riting of the report; and in the decision to submit the paper
or publication.
esultstudy population
ix different categories of practitioner were selected:
eneral practitioners (GPs), dentists, lung specialists, gas-
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igure 1. Study population ﬂowchart.J.-P. Collet et al.
roenterologists, anaesthetists and cardiologists. Of the
riginal database, 88% of practitioners were successfully
ontacted; 525 were excluded because they did not match
he inclusion criteria (Fig. 1). After the ﬁrst telephone
ontact, 608 practitioners declined for reasons including
ack of time or interest, refusal to participate in telephone
nterviews or surveys of public opinion as a general principle,
nd the secretary’s refusal. For the majority of physicians,
o reason was given.
Of the 2700 practitioners who participated in the inter-
iew, 2515 completed it. The overall rate of participation
as 82% (Fig. 1). The main reason for failure to complete the
uestionnaire was lack of time. The participation rate varied
idely, ranging from 65% for GPs to 97% for anaesthetists.
Practitioners were more often male and there was a het-
rogeneous distribution in age across specialties (Table 1).
The REGINA survey 701
Table 1 Demographic characteristics of physicians who participated in the interviews.
Dentists
(n = 422) (%)
General
practitioners
(n = 417) (%)
Lung specialists
(n = 423) (%)
Gastroenterologists
(n = 417) (%)
Anaesthetists
(n = 417) (%)
Cardiologists
(n = 419) (%)
Male sex 68 69 74 93 69 89
Age (years)
≤ 45 42 33 31 21 17 38
46—59 52 62 64 72 76 52
> 60 6 5 5 7 7 10
Type of practice
Hospital only 3 — 49 23 48 45
Ofﬁce only 92 — 26 46 48 30
Sole (vs. group) 48 NA 35 23 6 25
Urban practice 70 57 92 95 92 95
Geographical area
Paris region 19 14 22 20 22 30
Northern France 3 8 9 5 4 5
Western France 27 24 21 20 23 24
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TEastern France 20 20 18
Southern France 17 19 17
There was broad variation in terms of practice location, with
3% of dentists working exclusively in hospitals compared
with 48% of anaesthetists. The average length of interview
was 8mins. The study was undertaken between June and
September 2006.
Basic knowledge and recommendations
There was a dramatic heterogeneity in the rate of correct
answers to all basic questions ranging from 0% for dentists
to 52% for cardiologists; 95% of cardiologists could correctly
deﬁne a DES vs. only 7% of dentists (Fig. 2). Among other cat-
egories of practitioner, the correct answer was given by 39%
of GPs, 40% of lung specialists, 43% of gastroenterologists
and 56% of anaesthetists. Overall, the minimum duration of
dual APT was better known for DES than for BMS (Fig. 3).
Again, there was a large difference between cardiologists
and other categories of physician: less than 10% of dentists
Figure 2. Rate of correct answers to all basic questions and to
deﬁnition of a drug-eluting stent.
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ave the expected appropriate answers; however, only 54%
f cardiologists knew how to handle dual APT following BMS
lacement.
After multivariable logistic regression analysis, indepen-
ent correlates of correct answers to all basic questions
ere ‘being a cardiologist’ vs. ‘other practitioner’ (odds
atio [OR] 19.0, 95% conﬁdence interval [CI] 14.4—25.2;
< 0.0001), young age (≤ 45 vs > 60 years, OR 3.5, 95% CI
.9—6.4, p < 0.0001;≤ 45 vs > 50 to≤ 60 years, OR 1.9, 95%
I 1.3—2.6, p < 0.001), and male sex (OR 1.8, 95% CI 1.2—2.7,
< 0.01).
otal or partial interruption of dual APT
total of 21 scenarios were proposed, including 14 with
igh ischemic risk and seven with low ischemic risk fea-
ures. They are listed in the appendix with correct answers,
s deﬁned by the expert committee, in bold italics. Par-
ial (one of the two oral antiplatelet agents) or total (both
spirin and clopidogrel) interruption was the strategy cho-
en by 72% of practitioners about to perform an invasive or
igure 3. Rate of correct answers to minimum duration of dual
ral antiplatelet therapy with respect to type of stent.
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Figure 4. Rate of at least one total interruption of dual
antiplatelet therapy among each category of physician. Observed
and unjustiﬁed refers to the % of practitioners who chose total
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snterruption for at least one proposed scenario although it was not
ecessary and mandatory according to expert panel recommenda-
ion.
urgical procedure, although continuation of dual APT was
andatory in 47% of all situations (10 of 21). Total interrup-
ion was a particularly frequent strategy (22.0%), although
t was justiﬁed and expected in only 11.8% (4 of 21) of
linical scenarios given the high risk of bleeding (Fig. 4).
njustiﬁed total interruption was more frequently chosen by
pecialists compared with dentists or GPs (Fig. 4). A strat-
gy of total interruption was more frequently chosen in the
eriod of low ischemic risk (Q4—5, Q10—11, 15, Q18—19,
1, Q25—26, 30) compared to the high-risk period (31.1% vs.
3.7%, p < 0.0001); this trend was observed only among spe-
ialists, whereas similar rates were reported among dentists
nd GPs (Fig. 5).
The choice of postponing surgery or the invasive proce-
ure varied according to category of practitioner. Dentists
78%) and GPs (56%) displayed the highest rates compared
o lung specialists (27%), gastroenterologists (20%), anaes-
hetists (12%) and cardiologists (35%) (p < 0.0001 for all).
igure 5. Rate of total interruption of dual oral antiplatelet ther-
py according to periods of low and high ischemic risk of stent
hrombosis.
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ligure 6. Rate of correct answers to all questions according to
ajor risk of either thrombosis or bleeding vs. no risk.
Independent correlates of total interruption after multi-
ariable regression analysis, conducted separately for each
ategory of practitioner, were age for cardiologists (> 60
s≤ 45 years, OR 2.26, 95% CI 1.13—4.50, p = 0.02; and > 50
o≤ 60 vs≤ 45 years, OR 1.76, 95% CI 1.12—2.79, p = 0.015).
anagement of interruption and of
eintroduction of APT
nterruption of APT was usually planned for more than ﬁve
ays; 17% of the population who chose the interruption strat-
gy planned to interrupt for less than ﬁve days, 30% from
—9 days, and 25% more than 10 days prior to planned inter-
ention. There was no signiﬁcant difference with respect
o category of physician. Low-molecular-weight heparin was
hosen as the substitution therapy in more than two-thirds
f situations.
Large discrepancies were observed between categories
f practitioner as to whether reintroduction of APT was
ystematically advised. Only 51% of dentists and 67% of
astroenterologists systematically recommended rapid rein-
roduction, compared to 77% of anaesthetists, 84% of GPs,
8% of lung specialists and 92% of cardiologists.
Total interruption could be chosen either by the practi-
ioner alone or after requesting expert advice. Cardiologists
nd anaesthetists requested expert advice from gastroen-
erologists and surgeons, when indicated, in 73% and 72%, of
he situations, respectively, whereas lung specialists, anaes-
hetists and gastroenterologists requested expert advice
rom cardiologists in only 42, 32 and 54% of the situations,
espectively.
Concordance between answers from each practitioner
o high-risk situations in which they themselves were the
atient and they were not the patient was high. The
appa coefﬁcient ranged from 0.73 (0.67—0.79) for GPs,
.79 (0.73—0.85) for lung specialists and cardiologists, 0.80
0.75—0.86) for gastroenterologists, to 0.84 (0.78—0.89) for
naesthetists.orrect answer according to the period at risk
f stent thrombosis and to the bleeding risk
he high-risk situations were much better managed than the
ow-risk one (Fig. 6). There was a trend for under treat-
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ing patients exposed to a low-risk situation compared with
expert committee expectations. On average, there was a
twofold difference in the rate of correct answers between
the low- and high-risk situations, with a signiﬁcant correla-
tion between the rates of appropriate answers to the two
types of situations for all categories of practitioner.
High bleeding risk situations represented ﬁve (Q7, 11,
19, 20 and 29) of the 21 scenarios, of which three were
also high ischemic risk (Q11, 19 and 29). Interruption of
dual APT was mandatory in all situations except one (Q7),
for which postponement was the chosen strategy. The rate
of correct answers to all questions concerning the high
bleeding risk situation was signiﬁcantly less than for the
low bleeding risk one (p < 0001). However, signiﬁcant dif-
ferences were observed according to type of practitioner
(p < 0.001, Breslow-Day test) and practitioners tended to
continue dual APT irrespective of bleeding risk, especially
when high ischemic risk and high bleeding risk were present.
Compared to all situations bearing neither major
ischemic risk nor major bleeding risk (Q6, 12, 14, 17, 22,
28, 29, 31), the rate of correct answers to all situations
with either one major bleeding or one ischemic risk was
signiﬁcantly more (Q4—7, Q10—11, Q15, Q18—21, Q25—26,
Q30) (30.2% vs. 49.16%, p < 0.0001). In addition, there were
signiﬁcant differences according to type of practitioner
(p < 0.001, Breslow-Day test) (Fig. 6).
Discussion
The REGINA survey is the ﬁrst prospective evaluation of
dual APT discontinuation among a wide variety of French
practitioners who regularly deliver medical care to patients
with established CAD who require invasive cardiac or sur-
gical procedures. Both ischaemic and bleeding risks were
carefully weighted in selected and common real-life situa-
tions. Knowledge of recommendations regarding use of
dual APT after stent placement was poor overall, although
there were large discrepancies according to category of
practitioner. Misguided concerns about excessive procedure-
related bleeding led to a dramatic and inappropriate rate
of complete interruption of dual APT. As a consequence,
excessive use of substitution therapies that have not been
properly evaluated in randomised studies, leading to pro-
longed discontinuation of APT, was observed. Reassuringly,
scenarios of high risk were better managed than low-risk
ones (Fig. 6). Taken together, the ﬁndings suggest that ade-
quate management of dual APT interruption in patients who
require additional invasive cardiac or surgical procedures
depends greatly on the type of physician consulted, and
often on the physician’s age and type of practice (rural or
private vs. urban or hospital), suggesting a frequent lack
of information and probably also lack of communication
between the different physicians concerned with the care
of an individual patient. Scientiﬁc recommendations on the
use of APT in patients with DES clearly need further devel-
opment and dissemination to avoid adverse outcomes in
coronary patients at temporary risk of bleeding.
With the increasing use of DES and recent data on
the long-term beneﬁt of dual APT [17], discontinuation of
APT has become a great concern not only for cardiolo-
gists but for all practitioners in charge of patients with
a
o
d
c
i703
therothrombosis. Interruption of APT is mainly driven by
he potential risk of bleeding complications in the context
f planned surgery or any other intervention that incurs
n additional bleeding risk. However, the lack of prospec-
ive and scientiﬁc evaluation in the real world may account
or the notable discrepancies between physicians on how
o approach this dilemma. Consistent data are available
emonstrating the detrimental effect of complete APT dis-
ontinuation [1,2,18—20], although some clinical situations
equire further clariﬁcation, namely partial interruption of
ual APT [21—24]. For example, discontinuation of clopi-
ogrel after the recommended duration, while maintaining
spirin, is a real challenge given the suspected increase
f late DES thrombosis but the lack of scientiﬁc evidence
4,21,25—27].
There are clearly situations for which discontinuation of
ntiplatelet therapy is indicated, and careful assessment
f the relative risks of ischaemic and bleeding events is
ecessary to determine whether antiplatelet therapy conti-
uation or withdrawal is most appropriate. In the present
nvestigation, high- and low-risk ischaemic situations were
arefully chosen to avoid misunderstanding. In particular,
he high-risk situation corresponded to surgery soon after
ES implantation, a scenario with a well-established mor-
ality risk [21,23]. As a consequence, complete interruption
as rarely mandatory according to prespeciﬁed recom-
endations from the advisory board. However, the rate
f complete interruption was very high overall. Reassur-
ngly, situations with a high ischaemic risk were better
anaged than low-risk ones, although they are far less
requent in the real world. Indeed, patients with recent
tent placement who require immediate invasive care
ith potential bleeding are much fewer in number than
hose who had a stent implanted more than a year ear-
ier.
Not surprisingly, signiﬁcant differences in approach were
bserved with respect to the type of practitioner. With the
xception of dentists, practitioners who usually carry out
nvasive or diagnostic procedures with potential bleeding
isk were more likely to discontinue dual APT compared with
Ps. Although the very low rate among dentists is striking, it
hould be noted that there are 10 to 40 times more dentists
han any other type of practitioner in France; there are also
0 000 dentists for every 1000 lung specialists and every 100
nterventional lung specialists. In addition, considering that
ost dental procedures do not require discontinuation of
ual APT, it is reasonable to assume that the absolute num-
er of inappropriate complete interruptions of dual APT is
robably higher among dentists than for any other type of
ractitioner. Signiﬁcant differences between rates of com-
lete interruption between low- and high-ischaemic risk
ituations were observed for all types of practitioner except
or dentists. This intriguing ﬁnding suggests an additional
isk—that dentists are unlikely to make a decision to discon-
inue based on the patient’s clinical situation and rather
efer the patients to specialists. The low rate of discon-
inuation of dual APT reported among GPs is because they
re less likely to perform invasive procedures compared to
ther practitioners, but also because they do not make the
ecision themselves, instead referring the patient to a spe-
ialist. This last option was not evaluated in the present
nvestigation.
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One of the major consequences of complete interrup-
ion of dual APT is the use of ‘substitution therapies’, which
re sought to prevent acute coronary events in patients
ith stable CAD. Two different types of antithrombotic
egimen were chosen in the present investigation, given
revious recommendations—low-molecular-weight heparins
nd NSAIDs [28]. Neither of these treatments has been eval-
ated in a stable situation, nor has either proven efﬁcacy
n preventing stent thrombosis. Our study provides clear
vidence that substitution is a frequent strategy after the
ecision to interrupt dual APT has been made. It also shows
hat when substitution therapy is the preferred strategy, dis-
ontinuation continues for longer, leading to a prolonged
ime without any effective antiplatelet agents to prevent
cute stent thrombosis. Overall, these results highlight the
ack of clear guidance available for APT interruption during
nvasive procedures in patients with coronary stents [29].
Our investigation provides clear evidence that discon-
inuation of dual APT in patients undergoing additional
on-cardiac invasive or surgical procedures depends greatly
n the category of physician concerned and on whether
cientiﬁc recommendations have been developed for their
pecialty. However, despite the availability of recommen-
ations, inappropriate decisions about APT discontinuation
emain frequent. The most dramatic ﬁnding is the low
ate of correct answers to the ‘basic knowledge’ questions:
nly 7% of dentists could correctly deﬁne a DES and 5% of
ardiologists could not. Given the recent controversy on
he long-term safety of DES, continuing medical education
emains an urgent priority; education of patients may also
elp to improve physicians’ understanding and clinical prac-
ice! Speciﬁcally, knowledge of recommendations on the
se of APT in patients with stents requires improvement.
t appears likely that guidelines are effective in identify-
ng situations of high ischaemic risk but we also need to
etermine the bleeding risk associated with the type of
rocedure, particularly for planned surgery. Bleeding is an
ndependent correlate of mortality, especially in patients
ith CAD who are treated with antithrombotic therapies
11] and premature discontinuation of antiplatelet thera-
ies has been suggested as one of the potential mechanism
f death in patients who bleed [30]. The situation of high
leeding risk was not clearly identiﬁed by all practitioners
ho tended to continue dual APT in patients with high-risk
leeding features and who would have required interruption
f dual APT.
imitations
lthough we interviewed 1% of all active practitioners in
rance, no surgeons, rheumatologists or other specialists
ho perform invasive procedures requiring discontinuation
f APT were interviewed. However, there were no avail-
ble recommendations for theses specialties. Moreover, for
ome of the categories of physician interviewed, guidelines
n APT interruption have been only recently available, and
issemination of these recommendations was not optimal
t the time of the interview [13,16]. In addition, we did not
uote whether practitioners were aware of available rec-
mmendations. The risk of stent thrombosis and the debate
n DES is still ongoing, with new information released dur-
ng and after this survey that may have an impact on how
5
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hysicians weigh the risk/beneﬁt of APT interruption in their
atients [21,31—33]. All of these limitations may contribute
o the discrepancies we observed in responses to our ques-
ions. Nevertheless, we believe that the question of APT
nterruption remains poorly understood, with limited sci-
ntiﬁc knowledge, and uncertainty persists regarding the
ptimal strategies for the multiple presenting clinical situa-
ions [29]. Our survey provides a worrying but worthwhile
icture of the situation and should help further in bringing
ttention to this public healthcare issue. Our results apply
peciﬁcally to French physicians and one may have expected
different pattern in other countries,
onclusions
ur data highlight an urgent need to improve not only
uidelines but also practitioners’ basic knowledge to avoid
nnecessary risk for patients and communication between
hysicians and between patient and physicians. Although
erception of ischaemic risk is reasonably well established,
here is also a need to improve guidelines on identiﬁcation
f bleeding risk. In that respect, the results of the ongo-
ng STRATAGEM trial, [34] which randomly selects patients
ith established atherothrombosis to continue or discon-
inue chronic aspirin therapy in the context of planned
on-cardiac surgery, should be very helpful. Finally, we also
eed additional prospective large-scale trial randomising
lopidogrel discontinuation after one year of treatment fol-
owing DES implantation.
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ppendix A.
.1. Basic knowledge questions
1: What is a drug-eluting stent (DES)?
. An endovascular prosthesis coated with a controlled-
release polymer containing antiproliferative drugs
. An endovascular prosthesis cAPTed with a controlled-
release polymer containing antithrombotic drugs
. An endovascular prosthesis with progressive resorption
after placement
. An autoexpandable endovascular prosthesis
. Do not know
Q2: What is the minimum duration of dual oral
ntiplatelet therapy after bare-metal stent (BMS) place-
ent?
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1. 8 days
. 1 month
3. Between 2 months and up to 1 year
4. Life long
5. Do not know
Q3: What is the minimum duration of dual oral
antiplatelet therapy after DES placement?
1. 8 days
2. 1 month
. Between 2 months and up to 1 year
4. Life long
5. Do not know
Appendix B.
B.1. Questions for lung specialists Q4—Q9
Q4: A heavy smoker is referred to you for a bronchoscopy
to investigate haemoptysis. He has recently undergone
DES placement (< 1 month) and is currently being treated
with a combination of 75mg/d aspirin and 75mg/d clopi-
dogrel. What do you do? (Single answer)
1. You refuse to perform diagnostic bronchoscopy
. You agree to perform diagnostic bronchoscopy while
the patient continues to take dual APT
3. You agree to perform diagnostic bronchoscopy after the
patient temporarily stops taking aspirin
4. You agree to perform diagnostic bronchoscopy after the
patient temporarily stops taking clopidogrel
5. You agree to perform diagnostic bronchoscopy after the
patient temporarily stops taking dual APT
6. You do not know
Q5: A bronchus narrowing is found with a suspect mass
(non-haemorrhagic). A biopsy is required given the sus-
picion of an underlying cancer. What do you do? (Single
answer)
1. You recommend postponing the biopsy
2. You agree to perform the biopsy while the patient con-
tinues to take dual APT
3. You agree to perform the biopsy after the patient tem-
porarily stops taking aspirin
. You agree to perform the biopsy after the patient
temporarily stops taking clopidogrel
5. You agree to perform the biopsy after the patient tem-
porarily stops taking both aspirin and clopidogrel
6. You do not know
Q6: A patient is referred to you for bronchoalveolar
lavage because of a suspected pulmonary ﬁbrosis. They
underwent DES placement 18 months ago and are cur-
rently being treated with a combination of 75mg/d aspirin
and 75mg/d clopidogrel. What do you do? (Single answer)
1. You refuse to perform BAL
. You agree to perform BAL while the patient continuesto take dual APT
3. You agree to perform BAL after the patient temporarily
stops taking aspirin
4. You agree to perform BAL after the patient temporarily
stops taking clopidogrel
2
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. You agree to perform the BAL after the patient temporar-
ily stops taking both aspirin and clopidogrel
. You do not know
Q7: A transbronchus biopsy is necessary for diagnostic
onﬁrmation. What do you do? (Single answer)
. You recommend postponing the biopsy
. You perform the biopsy while the patient continues to
take dual APT
. You perform the biopsy after the patient temporarily
stops taking aspirin
. You perform the biopsy after the patient temporarily
stops taking clopidogrel
. You perform the biopsy after the patient temporarily
stops taking both aspirin and clopidogrel
. You do not know
Q8: Same question as Q7 but you are the patient. (Sin-
le answer)
. You recommend postponing the biopsy
. You undergo the biopsy while continuing to take dual APT
. You undergo the biopsy after temporarily stopping taking
aspirin
. You undergo the biopsy after temporarily stopping taking
clopidogrel
. You undergo the biopsy after temporarily stopping taking
both aspirin and clopidogrel
. You do not know
[Q9 was a duplicate of another question and was there-
ore removed from the questionnaire]
.2. Questions for anaesthetists Q10—Q14
10: A patient with a recent DES placement (< 1 month) is
eferred to you for a diagnostic colonoscopy to explore a
ild anaemia associated with black stools. They are cur-
ently being treated with a combination of 75mg/d aspirin
nd 75mg/d clopidogrel. The patient has been informed
f the risk. What do you do? (Single answer)
. You refuse to administer anaesthesia while the patient
continues to take aspirin and clopidogrel
. You agree to administer anaesthesia while the patient
continues to take aspirin and clopidogrel
. You agree to administer anaesthesia after the patient
temporarily stops taking aspirin but continues to take
clopidogrel
. You agree to administer anaesthesia after the patient
temporarily stops taking clopidogrel but continues to
take aspirin
. You agree to administer anaesthesia after the patient
temporarily stops taking both aspirin and clopidogrel
. You do not know
Q11: A malignant tumour of the right angle of the colon
s diagnosed and surgery is planned. The anaesthetist asks
ou what should be done regarding APT. (Single answer)
. You refuse to administer anaesthesia while the patientcontinues to take aspirin and clopidogrel
. You agree to administer anaesthesia while the patient
continues to take aspirin and clopidogrel
. You agree to administer anaesthesia after the patient
temporarily stops taking aspirin
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. You agree to administer anaesthesia after the patient
temporarily stops taking clopidogrel but continues to
take aspirin
. You agree to administer anaesthesia after the patient
temporarily stops taking both aspirin and clopidogrel
. You do not know
Q12: Same as Q10 but the time delay from stent place-
ent to colonoscopy is > 18 months. (Single answer)
. You refuse to administer anaesthesia while the patient
continues to take aspirin and clopidogrel
. You agree to administer anaesthesia while the patient
continues to take aspirin and clopidogrel
. You agree to administer anaesthesia after the patient
temporarily stops taking aspirin but continues to take
clopidogrel
. You agree to administer anaesthesia after the patient
temporarily stops taking clopidogrel but continues to
take aspirin
. You agree to administer anaesthesia after the patient
temporarily stops taking aspirin and clopidogrel
. You do not know
Q13: Same question as Q12 but you are the patient.
. You refuse to undergo anaesthesia while you continue to
take aspirin and clopidogrel
. You agree to undergo anaesthesia while you continue to
take aspirin and clopidogrel
. You agree to undergo anaesthesia after you temporarily
stop taking aspirin but continue to take clopidogrel
. You agree to undergo anaesthesia after you temporarily
stop taking clopidogrel but continue to take aspirin
. You agree to undergo anaesthesia after you temporarily
stop taking both aspirin and clopidogrel
. You do not know
Q14: The colonoscopy reveals a pedicle polyp (< 1 cm)
f the transverse colon without bleeding features but
hich may have accounted for the chronic bleeding. The
ecision is made to perform a polypectomy. What do you
o? (Single answer)
. You refuse to administer anaesthesia while the patient
continues to take aspirin and clopidogrel
. You agree to administer anaesthesia while the patient
continues to take aspirin and clopidogrel
. You agree to administer anaesthesia after the patient
temporarily stops taking aspirin but continues to take
clopidogrel
. You agree to administer anaesthesia after the patient
temporarily stops taking clopidogrel but continues to
take aspirin
. You agree to administer anaesthesia after the patient
temporarily stops taking aspirin and clopidogrel
. You do not know
.3. Questions for cardiologists Q15—Q2015: A patient who has recently undergone DES place-
ent (< 1 month) needs to have a tooth extraction. They
re currently being treated with a combination of 75mg/d
spirin and 75mg/d clopidogrel. What do you recommend?
Single answer)
5
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. You ask the patient to continue to take both aspirin
and clopidogrel before the extraction
. You ask the patient to temporarily stop taking both clopi-
dogrel and aspirin
. You ask the patient to temporarily stop taking aspirin but
to keep taking clopidogrel
. You ask the patient to temporarily stop taking clopidogrel
but to keep taking aspirin
. You ask for the tooth extraction to be postponed
. You do not know
Q16: Same question as Q15 but you are the patient.
Single answer)
. You agree to continue taking both aspirin and clopidogrel
before the extraction
. You agree to temporarily stop taking both clopidogrel and
aspirin
. You agree to temporarily stop taking aspirin but keep
taking clopidogrel
. You agree to temporarily stop taking clopidogrel but keep
taking aspirin
. You ask for the tooth extraction to be postponed
. You do not know
Q17: A patient needs to have impacted back teeth
xtracted. They have undergone DES placement 18
onths ago and are currently being treated with a combi-
ation of 75mg/d aspirin and 75mg/d clopidogrel. What
o you recommend? (Single answer)
. You request that the patient continues to take both
aspirin and clopidogrel before the extraction
. You suggest the patient temporarily stops taking both
clopidogrel and aspirin
. You suggest the patient temporarily stops taking aspirin
but keeps taking clopidogrel
. You suggest the patient temporarily stops taking
clopidogrel but keeps taking aspirin
. You ask for the dentist’s expert opinion
. You do not know
Q18: An anaesthetist asks for your expert opinion
ecause they have been asked to take care of a patient
ho needs a diagnostic colonoscopy (mild anaemia with
lack stools). The is patient has recently undergone DES
lacement (< 1 month) and is currently being treated by a
ombination of 75mg/d aspirin and 75mg/d clopidogrel.
hat do you recommend? (Single answer)
. You recommend administering anaesthesia and per-
forming the colonoscopy while the patient continues
to take aspirin and clopidogrel
. You recommend postponing the colonoscopy
. You recommend administering anaesthesia and perform-
ing the colonoscopy after the patient temporarily stops
taking aspirin but keeps taking clopidogrel
. You recommend administering anaesthesia and perform-
ing the colonoscopy after the patient temporarily stops
taking clopidogrel but keeps taking aspirin
. You recommend administering anaesthesia and perform-
ing the colonoscopy after the patient temporarily stops
taking both aspirin and clopidogrel
. You do not know
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Q19: A cancer of the right angle of the colon is diag-
nosed and surgery is planned. The anaesthetist asks for
your expert opinion. (Single answer)
1. You recommend that the surgery goes ahead while the
patient continues to take both aspirin and clopidogrel
. You recommend that the surgery is postponed
3. You recommend that the surgery is performed after the
patient temporarily stops taking aspirin but continues to
take clopidogrel
4. You recommend that the surgery is performed after the
patient temporarily stops taking clopidogrel but contin-
ues to take aspirin
5. You recommend that the surgery is performed after the
patient temporarily stops taking both aspirin and clopi-
dogrel
6. You do not know
Q20: What would you have recommended to the
anaesthetist if the time delay from DES placement to
colonoscopy had been>18 months and the patient was
stable? (Single answer)
1. You recommend administering anaesthesia and perform-
ing the colonoscopy while the patient continues to take
aspirin and clopidogrel
2. You recommend postponing the colonoscopy
3. You recommend administering anaesthesia and perform-
ing the colonoscopy after the patient temporarily stops
taking aspirin but continues to take clopidogrel
. You recommend administering anaesthesia and per-
forming the colonoscopy after the patient temporar-
ily stops taking clopidogrel but continues to take
aspirin
5. You recommend administering anaesthesia and perform-
ing the colonoscopy after the patient temporarily stops
taking both aspirin and clopidogrel
6. You do not know
B.4. Questions for dentists Q21—Q24
Q21: A patient with a recent DES placement (< 1 month)
needs to have a simple tooth extraction (not impacted).
They are being treated with a combination of 75mg/d
aspirin and of 75mg/d clopidogrel. What do you do? (One
possible answer)
1. You ask the patient to temporarily stop taking both
aspirin and clopidogrel before the tooth extraction
2. You ask the patient to temporarily stop taking clopidogrel
before the tooth extraction
. You perform the tooth extraction with careful
haemostasis and without interruption of APT
4. You refuse to perform the tooth extraction and you refer
the patient to their GP or cardiologist for expert advice
5. You ask the patient to temporarily stop taking aspirin
before the tooth extraction
6. You don’t know
Q22: Same as question Q21 but the time delay from
stent placement to extraction is > 18 months and there
are two impacted back teeth to be extracted. What do
you do? (One possible answer)
1. You ask the patient to temporarily stop taking both
aspirin and clopidogrel before the tooth extraction
5
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. You ask the patient to temporarily stop taking clopi-
dogrel before the tooth extraction
. You perform the tooth extraction with careful
haemostasis and without interruption of APT
. You refuse to perform the tooth extraction and you refer
the patient to their GP or cardiologist for their expert
advice
. You ask the patient to temporarily stop taking aspirin
before the tooth extraction
. You do not know
Q23: Same as Q21, but you are the patient. What do
ou do? (One possible answer)
. You would temporarily stop taking both aspirin and clopi-
dogrel before the tooth extraction
. You would temporarily stop taking clopidogrel before the
tooth extraction
. You would continue to take both aspirin and clopidogrel
before the tooth extraction
. You would ask your cardiologist for advice
. You would temporarily stop taking aspirin before the
tooth extraction
. You do not know
Q24: Same as Q22, but you are the patient. What do
ou do? (One possible answer)
. You would temporarily stop taking both aspirin and clopi-
dogrel before the tooth extraction
. You would temporarily stop taking clopidogrel before the
tooth extraction
. You would continue to take both aspirin and clopidogrel
before the tooth extraction
. You would ask your cardiologist for advice
. You would temporarily stop taking aspirin before the
tooth extraction
. You do not know
.5. Questions for gastroenterologists
25—Q29
25: A patient with a recent DES stent placement (< 1
onth) is referred to you for diagnostic gastroscopy to
nvestigate why they are producing black stools. They are
eing treated with a combination of 75mg/d aspirin and
5mg/d clopidogrel. What would you do? (Single answer)
. You refuse to perform the gastroscopy and you start the
patient on proton pump inhibitor (PPI) treatment
. You agree to perform the gastroscopy while the
patient continues with dual APT and you start the
patient on PPI treatment
. You agree to perform the gastroscopy after the patient
temporarily stops taking aspirin and you start the patient
on PPI treatment
. You agree to perform the gastroscopy after the patient
temporarily stops taking clopidogrel and you start the
patient on PPI treatment
. You agree to perform the gastroscopy after the patient
temporarily stops taking dual APT and you start the
patient on PPI treatment
. You do not know
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Q26: A non-bleeding ulcer is discovered. You are asked
o perform a biopsy to investigate a possible underlying
ancer. What do you do? (Single answer)
. You refuse and you recommend postponing the biopsy
. You agree to perform the biopsy while the patient
continues with dual APT and you start the patient on
PPI treatment
. You perform the biopsy after the patient temporarily
stops taking aspirin
. You perform the biopsy after the patient temporarily
stops taking clopidogrel
. You perform the biopsy after the patient temporarily
stops taking both aspirin and clopidogrel You do not know
Q27: Same question as Q26 but you are the patient.
hat would you do? (Single answer)
. You refuse to have the biopsy and advise that it be post-
poned
. You have the biopsy while continuing to take dual APT
and you start PPI treatment
. You have the biopsy after temporarily stopping taking
aspirin
. You have the biopsy after temporarily stopping taking
clopidogrel
. You have the biopsy after temporarily stopping taking
both aspirin and clopidogrel
. You do not know
Q28: A patient is referred to you for diagnostic
olonoscopy because of the presence of blood in their
tools. This patient has undergone DES placement 18
onths before and is currently being treated with a com-
ination of 75mg/d aspirin and 75mg/d clopidogrel. What
o you recommend? (Single answer)
. You refuse to perform the colonoscopy while the patient
continues to take dual APT
. You agree to perform the colonoscopy while the patient
continues to take dual APT
. You agree to perform the colonoscopy after the patient
temporarily stops taking aspirin
. You agree to perform the colonoscopy after the
patient temporarily stops taking clopidogrel
. You agree to perform the colonoscopy after the patient
temporarily stops taking both aspirin and clopidogrel
. You do not know
Q29: A pedicle polyp (< 1 cm) is discovered in the trans-
erse colon. The decision to perform a polypectomy is
ade. What do you do? (Single answer)
. You refuse to perform the polypectomy while the patient
continues to take dual APT
. You agree to perform the polypectomy while the patient
continues to take dual APT
. You agree to perform the polypectomy after the patient
temporarily stops taking aspirin
. You agree to perform the polypectomy after the
patient temporarily stops taking clopidogrel
. You agree to perform the polypectomy after the patient
temporarily stops taking both aspirin and clopidogrel
. You do not know
FJ.-P. Collet et al.
.6. Questions for GPs Q30—Q32
30: A patient with a recent DES placement (< 1 month)
eeds to have a simple tooth extraction (not impacted).
hey are being treated with a combination of 75mg/d
spirin and 75mg/d clopidogrel. What do you recommend?
Single answer)
. You agree to the tooth extraction after the patient tem-
porarily stops taking dual APT
. You ask the patient to temporarily stop taking clopidogrel
before the tooth extraction
. You request that the patient continues to take dual
APT before the tooth extraction
. You ask for the expert advice of a cardiologist
. You recommend the patient temporarily stops taking
aspirin before the tooth extraction but keeps taking
clopidogrel
. You do not know
Q31: Same question as Q30 but you are the patient.
hat would you do? (Single answer)
. You agree to the tooth extraction after stopping taking
dual APT
. You agree to temporarily stop taking clopidogrel before
the tooth extraction
. You continue taking dual APT before the tooth extraction
. You ask for the expert advice of a cardiologist
. You suggest temporarily stopping taking aspirin before
the tooth extraction but keep taking clopidogrel
. You do not know
Q32: Same as question Q30 but the time delay from
ES placement to extraction is > 18 months and there are
wo impacted back teeth to be extracted. What do you
o? (Single answer)
. You agree to the tooth extraction after the patient tem-
porarily stops taking dual APT
. You ask the patient to temporarily stop taking clopi-
dogrel before the tooth extraction
. You ask the patient to continue with dual APT during the
tooth extraction
. You ask for the expert advice of a cardiologist
. You recommend the patient temporarily stops taking
aspirin before the tooth extraction but keeps taking
clopidogrel
. You do not know
ppendix C.
.1. Questions related to complete
nterruption of dual APT
or lung specialists If the answers to Q4 or
Q5 or Q6 or Q7 or Q8 = 3
or 4 or 5, then ask Q33
to Q36 and Q38or anaesthetists If the answers to Q10
or Q11 or Q12 or Q13 or
Q14 = 3 or 4 or 5, then
ask Q33 to Q38
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For cardiologists If the answers to Q15 or
Q16 or Q17 = 2 or 3 or
4, then ask Q33 to Q37
If the answers to Q18 or
Q19 or Q20 = 3 or 4 or
5, then ask Q33 to Q37
For dentists If the answers to Q21
or Q22 or Q23 or
Q24 = 1 or 2 or 5, then
ask Q33 to Q36
For gastroenterologists If the answers to Q25
or Q26 or Q27 or Q28 or
Q29 = 3 or 4 or 5, then
ask Q33 to Q36 and Q38
For general practitioners If the answers to Q30
or Q31 = 1 or 2 or 5,
then ask Q33 to Q36
Q33: Do you regularly inform the patient about the
potential thrombotic risk after they stop taking APT?
1. Yes
2. No
3. Do not know
Q34: For how long should the patient stop taking dual
APT before surgical intervention?
I I I days
Q35: Do you use substitution therapy?
1. Yes
i. Low-molecular-weight heparin
ii. Non-steroidal anti-inﬂammatory drug (Cébutid®)
2. No
3. Do not know
Q36: Would you ask your patient to resume taking dual
APT after surgical intervention?
1. Yes
2. No
3. Do not know
For cardiologists (Q15 or Q16 or Q17 = 2 or 3 or 4; Q18 or
Q19 or Q20 = 3 or 4 or 5) or anaesthetists
Q37: Would you ask for expert advice from a dentist
or gastroenterologist?
1. Yes
2. No
3. Do not know
For lung specialists (Q4 or Q5 or Q6 or Q7 or Q8 = 3 or 4
or 5), anaesthetists (Q10 or Q11 or Q12 or Q13 or Q14 = 3 or
4 or 5) and gastroenterologists (Q25 or Q26 or Q27 or Q28
or Q29 = 3 or 4 or 5)
Q38: Would you ask for expert advice from a cardiolo-
gist?
1. Always
2. Depends on the situation
3. Never
4. Do not knowReferences
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